MYGN:NGS-Myriad Genetics Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 24.9

Change

0.00 (0.00)%

Market Cap

USD 1.17B

Volume

0.60M

Analyst Target

USD 15.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-5.85 (-1.21%)

USD 42.12B
ICLR ICON PLC

+0.36 (+0.12%)

USD 23.70B
ILMN Illumina Inc

+5.07 (+3.72%)

USD 20.73B
NTRA Natera Inc

+3.54 (+2.80%)

USD 15.55B
EXAS EXACT Sciences Corporation

+1.95 (+2.94%)

USD 12.56B
MEDP Medpace Holdings Inc

+5.30 (+1.57%)

USD 10.28B
RDNT RadNet Inc

+1.00 (+1.48%)

USD 5.13B
SHC Sotera Health Co

+0.22 (+1.41%)

USD 4.75B
NEOG Neogen Corporation

+0.13 (+0.87%)

USD 3.61B
GH Guardant Health Inc

+0.36 (+1.65%)

USD 2.82B

ETFs Containing MYGN

HEP:CA 6.18 % 0.83 %

N/A

N/A
MXF:CA 4.70 % 0.74 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 4.22 % 0.00 %

+0.07 (+0.00%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.22 % 0.00 %

N/A

USD 6.11M
GNOG:LSE Global X Genomics & Biote.. 4.03 % 0.00 %

+0.04 (+0.00%)

USD 6.13M
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.16 (+0.00%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.09% 85% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.09% 85% B 87% B+
Trailing 12 Months  
Capital Gain 7.65% 78% C+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.65% 76% C+ 62% D
Trailing 5 Years  
Capital Gain -6.74% 70% C- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.74% 70% C- 44% F
Average Annual (5 Year Horizon)  
Capital Gain 11.45% 61% D- 70% C-
Dividend Return 11.45% 61% D- 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 63.21% 39% F 25% F
Risk Adjusted Return 18.12% 71% C- 54% F
Market Capitalization 1.17B 74% C 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.00 48% 29%
Price/Book Ratio 2.24 47% 43%
Price / Cash Flow Ratio -19.96 85% 88%
Price/Free Cash Flow Ratio -8.96 81% 83%
Management Effectiveness  
Return on Equity -29.41% 63% 40%
Return on Invested Capital -16.94% 68% 35%
Return on Assets -6.60% 69% 38%
Debt to Equity Ratio 4.92% 83% 78%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector